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Abstract
Inhibition of sickle hemoglobin polymerization is a major target for therapeutic approaches in sickle
cell anemia. Toward this goal, initial efforts at pharmacological elevation of fetal hemoglobin (HbF)
has shown therapeutic efficacy. In order to identify well tolerated, novel agents that induce HbF in
patients, we developed a high-throughput screening approach based on induction of γ-globin gene
expression in erythroid cells. We measured γ-globin transcription in K562 cells transfected with
either γ promoter elements fused with the locus control region (LCR) hypersensitivity site-2 and
luciferase reporter gene (HS2γ) or a β-yeast artificial chromosome in which the luciferase reporter
gene was recombined into the γ-globin coding sequences (γYAC). Corresponding pharmacological
increases in HbF protein were confirmed in both K562 cells and in human primary erythroid
progenitor cells. Approximately 186,000 defined chemicals and fungal extracts were evaluated for
their ability to increase γ gene transcription in either HS2γ or γYAC models. Eleven distinct classes
of compounds were identified, the majority of which were active within 24 - 48 hours. The short
chain hydroxamate-containing class generally exhibited delayed maximal activity, which continued
to increase transcription up to 120 hours. The cyclic tetrapeptide OSI-2040 and the hydroxamates
were shown to have histone deacetylase inhibitory activity. In primary hematopoietic progenitor cell
cultures, OSI-2040 increased HbF by 4.5 fold at a concentration of only 40 nM, comparable to the
effects of hydroxyurea at 100 uM. This screening methodology successfully identifies active
compounds for further mechanistic and preclinical evaluation as potential therapeutic agents for
sickle cell anemia.
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albumin; PBS: phosphate buffered saline; αMEM: α—modified Eagles media; DTT: 1,4-
dithiothreitol; PMSF: phenylmethylsulfonylfluoride; TMB: 3.3′, 5. 5′-tetramethylbenzidine; SCF:
stem cell factor; GADD153: growth-arrest-and-DNA-damage 153; GST-Ya: glutathione S-
transferase Ya; HMO: heme mono-oxygenase; HSP70: heat shock protein 70 HIF-1 RE hypoxia
inducible factor 1 response elment; NF-AT RE: nuclear factor AT response element; NF-kB RE:
nuclear factor kappa-B response element; XRE: xenobiotic element; DMEM: Dulbecco modified
Eagle’s medium; ANOVA: analysis of variance; EC50: half maximal effective concentration; IC50:
half maximal inhibitory concentration; PHA: proprionic hydroxamic acid; MMS: methane methyl
sulfonate; AH: aryl hydrocarbon receptor; RT-PCR: reverse transcriptase - polymerase chain
reaction; HDA: histone deacetylase; e.l.i.s.a.: enzyme-linked immunosorbent assay
INTRODUCTION
Through large-scale robotic screening we have sought to identify and characterize, at the
molecular level, chemical compounds which increase expression of fetal γ-globin. Fetal
hemoglobin augmenting agents are useful in the management of sickle cell anemia and β-
thalassemias to compensate for defects in the β chain of adult hemoglobin. Sickle cell disease
results from a change at codon 6 of the adult β-globin gene so that a glutamate is replace by a
valine (HbA to HbS) and afflicts 1 in 400 Afro-Americans. The altered β-globin protein
aggregates to produce an irreversible deformation of red blood cell morphology and a vaso-
occulsive disease with severe morbidity [1]. β-thalassemias arise from a wide variety of genetic
mutations which result in either the loss or reduced expression of the β-globin gene.
Thalassemia major, also known as Cooley’s anemia, is characterized by marked anemia, severe
hemolysis and ineffective erythropoiesis. Worldwide 240 million people are heterozygous for
these hemoglobinopathies and these disorders are being actively selected for by vivax and
falciparum malaria [2].
The human β-like globin genes (ɛ,γ,δ,β) and the sequence designated as the locus control region
(LCR) are clustered on ~100kb of chromosome 11 (Figure 1). During embryonic and fetal
development, globin genes are expressed in a temporal and tissue-specific fashion, which
requires switches in both α- and β-like globin expression so that sequential appearance of
embryonic (ζ2ɛ 2,2ɛ 2α and 2ζγ2), then fetal (α 2γ2) and then finally the adult forms (α2β2 and
α2δ 2) of hemoglobin occur [3,4]. Developmental regulation of the β-globin gene cluster is
mediated by several mechanisms. Sequences (enhancers and silencers) both within and
immediately flanking the genes themselves confer tissue and temporal specificity [5–8]. A 20
kb region 5′ of the β-globin locus, termed the locus control region (LCR) is defined by five
major DNase I hypersensitive sites (HS-I to HS-V) and has been shown to be critical for high
level, tissue-specific globin gene expression[9–11]. The individual genes of the β-globin locus
compete for physical association with the LCR, most likely through the interaction of
transcription factors which bind the LCR and the individual globin promoters [12,13].
In man, there is compelling evidence, genetic and pharmaceutical, that increasing expression
of γ-globin has clinical benefit in both sickle cell anemia and β-thalassemia [14,15]. In normal
individuals, between 1 and 3% of mature red blood cells express fetal γ-globin. In contrast,
adults with an asymptomatic condition termed hereditary persistence of fetal hemoglobin
(HPFH), exhibit high levels of fetal γ-globin. Based on such clinical studies, it has been
calculated that an induction of γ-globin gene expression to approximately 10 - 20% (or a 3 –
5 fold increase from individual baseline) of the adult β-globin level will significantly ameliorate
the symptoms of sickle cell disease [16]. While the cis-acting DNA elements required for γ-
globin transcription and HPFH have been well defined [17–24], the identity of factor(s) which
compete for these DNA elements and signaling pathways being modulated under physiological
conditions of low and high HbF synthesis, remain unclear. Competition of linked γ and β genes
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appears to be mediated by multiple elements within the human γ globin promoter [17] and
likely requires recruitment of repressor factors [25] which in turn recruit histone deacetylases.
Several pharmacological approaches seeking to up-regulate HbF have been developed. These
include the DNA methyltransferase inhibitor 5′-aza-cytidine [26,27], the ribonucleotide
reductase inhibitor hydroxyurea [28], short chain fatty acids such as butyric acid [29] and a
number of other cytostatic agents. The effective concentration of these agents can be variable
from individual to individual and these agents can show steep dose response profiles with
relatively narrow margins of safety. As a result, we sought to identify new agents which
augment HbF, to better define mechanisms by which pharmacological increases in HbF may
be afforded and asked the question whether compound cytotoxicity was a requirement for
induction of γ-globin transcription. Cell-based γ-globin transcription assays combined with
high-throughput screening were used to evaluate >186,000 compounds and fungal extracts.
Structurally distinct classes of compounds were identified which induce γ-globin transcription
and HbF accumulation, through diverse mechanisms of action. The data support models where
chromatin remodeling and/or delayed erythroid cell cycling can lead to increased HbF
expression through both transcriptional and post-transcriptional mechanisms.
MATERIALS AND METHODS
Identification of γ-globin-inducing compounds and extracts
The HS2 enhancer element of the LCR and proximal promoter sequences from the γ-globin
gene [30] were fused to the luciferase ‘reporter’ gene from H. pyralis [31]. The TK-neo gene,
present in cis on the reporter plasmid, was used as the selectable marker for mammalian cell
transfection. Human K562 cells, which display early erythroid and myeloid progenitor
markers, were stably electroporated to express HS2γ-luciferase. Luciferase-‘tagged’ γ-globin
YAC (γYAC) was constructed as previously described [32] where the luciferase gene was
recombined into YAC DNA 3′ of the γA promoter within the context of the full β-globin locus.
γYAC DNA was introduced into K562 cells and murine erythroleukemia (MEL) cells by
protoplast fusion and cells selected for puromycin resistance. Individual clonal lines were
evaluated by (i) basal luciferase expression; (ii) faithful integration of linear DNA as
determined by Southern hybridization; and (iii) inducible regulation of the integrated reporter
construct by hemin and 5-azacytidine (4 – 6 fold for HS2γ and >3 fold for γYAC). Expression
levels from multiple K562 lines expressing HS2γ or γYAC genes were suitable for high
throughput screening (HTS), while expression levels of γYAC in MEL-derived clones were
insufficient.
Chemical compounds were synthesized as discrete compounds, dissolved in neat dimethyl
sulfoxide (DMSO) and were screened on an individual basis at a concentration of ~12 uM.
Fungal extracts were prepared by freeze drying the fermentation material, broth and mycelia
together, followed by extraction with methanol. Extracts were dried and subjected to solvent
fractionation to provide three crude fractions (water-methanol, chloroform and hexane) which
were tested for biological activity at a 1:4 dilution of the starting culture volume (N/4). Active
fractions were further purified by reverse-phase HPLC. Full characterization of select
compounds was achieved using mass spectrometry and NMR techniques.
HS2γ/K562 and γYAC/K562 cells were plated at 10,000 cells per well in phenol red free
RPMI-1640 media, 2% FCS (Hyclone), 20 mM l-glutamine, penicillin (100 units/ml),
streptomycin (100 ug/ml), 20 mM HEPES, pH 7.4 in 96-well microtiter plates. Cells were
induced with compound (~12 uM) or fungal extract (N/4) for a period of 24 hours. The final
compound solvent concentration was 0.2% DMSO, which was used as the negative control.
The positive control was 1 uM azacytidine. Upon completion of induction period, luciferase
buffer was added to each well to achieve a final concentration of 100 mM Tris-acetate, pH 7.9,
Haley et al. Page 3
Biochem Pharmacol. Author manuscript; available in PMC 2006 January 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
20 mM magnesium acetate, 2 mM EGTA, 1% Brij 58, 100 mM 2-mercaptoethanol, 36 mM
ATP, 150 uM luciferin. Cells were allowed to lyse for 5 min at room temperature after which
the chemiluminescent signal was measured (Dynatech Lab ML1000- medium gain setting). A
preliminary screen of approximately 5,000 compounds was performed, incorporating internal
controls on each microtiter plate. These studies defined criteria to accept or reject high-
throughput screen data, requiring that: 1) penicillic acid or 5-azacytidine induced HS2γ reporter
gene expression >4 fold or γYAC expression >2 fold; 2) that the baseline signal was >0.05
luminometer units and; 3) that the coefficient of variation of controls on each microtiter plate
was <20%.
Cytotoxicity assays
MTT- (3-[4,5 Dimethylthiazol-2-yl-]-2,5 diphenyl tetrazolium bromide), a commonly used
colorimetric substrate, was used to measure mitochondrial respiration in order to assess cell
viability. Cells were plated as described for the luciferase reporter gene assays. After incubation
with test compounds for 24 and 48 hrs, 20 ul of 3 mg/ml MTT was added and cells incubated
for 2 hours at 37 °C, 5% CO2. One hundred microliters of 10% SDS was added to all wells for
4 hours at 37 °C to allow for lysis and solubilization of MTT. Mitochondrial conversion of
MTT was assessed by measurement of light absorbance at 540 nM. Background (from the
phosphate buffered saline control) was subtracted and the data expressed as % inhibition of
cell growth.
HbF e.l.i.s.a.. of K562 hypotonic lysates
K562 cells were exposed in duplicate to compound for a period of 4 days. Cells were collected
by centrifugation (1000 x g; 5 minutes), media aspirated, cells washed with phosphate buffered
saline (PBS) and the cell pellet lyzed in ice cold H2O by vortexing for ~40s. Nuclei were
removed by centrifugation (13,000 x g; 4 °C for 4 minutes). Cleared lysate was removed,
protein concentration determined and extracts stored at − 70 °C. Horseradish peroxidase (HRP)
conjugated monoclonal antibody to HbF (Isolabs/Wallace) was used for e.l.i.s.a. determination
of HbF concentration. Anti HbF is approximately 100 times more reactive to HbF than HbA.
Standard curves were generated using HbF standard (~10% HbF, 90% HbA) serially diluted
1:2 in 25 ug/ml BSA from 1 ug/ml HbF to 0.015 ug/ml HbF. 25 ug/ml BSA served as the assay
background control. Hypotonic lysates were diluted 25 ug/ml. Protein samples were added in
triplicate to Immulon-4 microtiter plates for colorimetric detection or Microlite II microtiter
plates for chemiluminescent detection (Dynex Technologies), using an excess of 0.1M
Na2HCO3 , pH 9.0 at room temperature for 2 hours. Plates were washed 4 times with 50 mM
Tris pH 8.0, 150 mM NaCl and 0.05% Tween-20 (TST). Anti-HbF was diluted 1:1000– 1:2000
in TST containing 1 % BSA (Fraction V) and 100 ul was added to each well, incubated for 2
hrs at room temperature, washed 4 times with TST and HRP substrate added. For colorimetric
detection, 100 ul of TMB substrate (Kirkegaard & Perry Laboratories) was added and incubated
for 30 minutes, quenched by the addition of 20ul 4N H2SO4 and read at 450nm/630nm. For
chemiluminescent detection 100 ul of complete LBA (Pierce Chemical Co.) was added per
well and measured 2 hrs post substrate addition. Correlation coefficients of standard curves
were 0.95 – 1.0 and not accepted if below 0.9.
Human primary blood progenitor culture
A two phase liquid culture system was used [33] with modification. Human blood partially
enriched for mononuclear cells (buffy coat) was diluted 1:1 with sterile PBS layed over 1.077
g/ml Ficoll (Invitrogen Corporation) and centrifuged at ~300 x g. Mononuclear cells at the
Ficoll-aqueous interface were removed, diluted with PBS, collected by centrifugation (300 x
g) and washed twice with PBS. Mononuclear cells containing erythroid progenitors from 2
units of blood were cultured in 80 mls ‘Phase I’ medium comprising: α modified Eagles media
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(αMEM; Invitrogen Corporation), 10% FCS (Stem Cell Technologies), 20 mM l-glutamine,
penicillin (100 units/ml), streptomycin (100 ug/ml), human cytokines (R&D Systems Inc.) 10
ng/ml IL-3, 10 ng/ml IL-6, 10 ng/ml granulocyte colony stimulating factor (G-CSF), 10 ng/ml
granulocyte-macrophage colony stimulating factor (GM-CSF), 20 ng/ml stem cell factor (SCF)
and 1 ug/ml cyclosporin A (Cayman Chemical Corp.). Phase I culture was expanded for 5 – 7
days, collected by centrifugation, washed twice in αMEM and transferred to ‘Phase II’ medium
comprising: αMEM, 10 – 30% FCS, 20 mM l-glutamine, penicillin (100 units/ml),
streptomycin (100 ug/ml), 1U/ml erythropoietin (EPO), 10 ng/ml SCF, 1 uM dexamethasone,
10 uM β-mercaptoethanol. The effect of compound on HbF in primary cultures was assessed
by exposing cells plated in Phase II media at 3 x 106 cells/ml, 5% CO2, 37degC, in a humidied
incubator, to a range of compound concentrations for 4 days (corresponding to days 4 to 8 in
Phase II).
K562 extract preparation and protein blotting
To measure histone acetylation, K562 cells (1 x 107 cells) were exposed to compounds for 24
hours. Cells were pelleted by centrifugation (500 x g, 5′), washed once with PBS followed by
resuspension in 10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT and 1.5
mM PMSF. HCl was added to 0.2 M for 30’ at 4degC. The extract was subjected to
centrifugation at 11,000 x g, for 10’ at 4degC. The supernatant fraction was dialyzed against
0.1M acetic acid (once for 1 hour), followed by dialysis against water (three times). Cell
extracts were subjected to SDS-PAGE, transferred to nitrocellulose membrane and incubated
with anti-acetyl histone antibody (Upstate Biotechnology) for 2 hours at room temperature.
Primary antibody incubation was followed by incubation with the appropriate HRP-conjugated
secondary antibody for 1 hour at room temperature and chemiluminescent detection (ECL;
Amersham Bioscience).
Stress gene profiling
HepG2 cells were stably transfected with individual reporter gene constructs employing the
luciferase gene under the control of the stress-responsive promoters for jun, growth-arrest-and-
DNA-damage 153 (GADD153), glutathione S-transferase Ya (GST Ya), heme mono-
oxygenase (HMO), heat shock protein 70 (HSP70) or the hypoxia inducible factor 1 (HIF-1
RE), nuclear factor AT (NF-AT RE), nuclear factor kappa-B (NF-kB RE) or xenobiotic (XRE)
response elements. Stably transfected clonal cell lines were isolated and selected for
appropriate response to 2 or more known modulators of the particular promoter element. Assay
conditions for each cell line were optimized for exposure time, serum concentration and cell
number.
Cells were plated onto white 96-well microtiter plates precoated with collagen at either 10,000
(GADD153, HIF-1 RE) or 20,000 cells / well (JUN, GST Ya, HSP70, HMO, NF-AT RE, NF-
kB RE, XRE) in 150 ml DMEM medium supplemented with L-glutamine, non-essential amino
acids and either 1 % (GADD153, GST Ya, HIF1RE, HMO, NF-ATRE, NF-kBRE, XRE) or
10 % (JUN, HSP70) fetal calf serum. After 24 hr incubation (37 °C, 5% CO2) the cells were
transferred to a fully robotic liquid and plate handling station where compounds were added
in triplicate at 6 concentrations in a 5-fold dilution range. The plates were further incubated
for either 6 hr (HMO), 8 hr (JUN, GADD153, GST Ya, NF-AT RE, NF-κB RE) 16 hr (HSP70,
XRE) or 24 hr (GST Ya, assayed at two different time points) and luciferase assays performed.
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RESULTS
Identification of compounds which increase γ-globin transcription in K562 and primary
progenitor cells
Our initial goal was to identify novel agents which induce γ-globin transcription through
random high-throughput screening of >186,000 entities and to categorize their mechanisms of
action. Two assay approaches were used: 1) a fusion of the LCR hypersensitivity site 2 enhancer
with the γ proximal promoter (HS2γ) 5′ to a luciferase reporter gene (Figure 1A); and 2) a
βYAC-based approach in which the luciferase reporter gene was integrated by homologous
recombination 3′ of the γ-globin promoter within the context of the full β-globin locus (Figure
1B; ref. 32). Extracts and compounds were evaluated and selected according the scheme shown
in Figure 2, where inductions of >4 fold for HS2γ and of >2 fold for γYAC were required for
further investigation of the test agent. Approximately 96,000 extracts from fungal, marine, seed
and herbal libraries and 48,400 compounds from chemical libraries were screened in the γYAC/
K562 assay and approximately 23,000 extracts and 31,000 compounds were screened in the
HS2γ/K562 assay. Extracts or compounds which increased γ-globin reporter activity greater
than four fold in K562/HS2γ cells or two fold in K562/γYAC cells, as compared with vehicle
control (0.2% DMSO), were selected for further evaluation. The frequency distribution of the
fold transcription increases resulting incubation with chemical compound or fungal extracts
are shown in Figure 3. The y-axis records fold induction relative to control. Compounds or
extracts are distributed along the x-axis, which has no units. Most extracts and compounds had
little or no effect on γ-globin gene expression and showed a normal distribution centering on
1.0, or no fold induction. The scales between panels differ due to the increased sensitivity of
HS2γ over γYAC and the often larger fold inductions observed with fungal extract mixtures
relative to single chemical compounds. The enhanced activity of fungal extracts is most likely
due to the sensitivity of the assay to specific classes of cytotoxic compounds and to the
multiplex nature of whole fungal extracts (data not shown). The frequencies of identifying
positively scoring compounds and natural product extracts in the automated screening approach
were 1% and 2.5% respectively.
Active fungal culture extracts were prioritized on the basis of efficacy, potency and cytotoxicity
at 24 and 48 hour time points. Extracts were dereplicated on the basis of HPLC retention time
to eliminate previously identified activities. From the 59 purified fungal metabolites, five
potent and efficacious activities were characterized (not shown). These comprised a furanone
(5-[1,2-dimethyl-propenyl]-5hydroxy-4methoxy-5H-furan-2-one), an isoflavone (7-
hydroxy-3-[4-hydroxy-phenyl]-chromen-4-one), a substituted phenol (1-[2,4,6-trimethoxy-
phenyl]-but-2-en-1-one), a dihydropyranone (acetic acid 2-[8-methyl-9-oxa-bicyclo[4.2.1]
nona-2,4-dien-7yl]-6oxo-3,6dihydro-2H-pyran-3-yl-ester) and a cyclic tetrapeptide
(OSI-2040; cyclo-[N-O-methyl-L-Trp-L-Ile-D-Pip-L-2-amino-8-oxo-decanoyl]). Of the
fungal metabolites, only OSI-2040 showed sufficient efficacy, potency and differential
cytotoxicity to warrant further study. OSI-2040, a cyclic tetrapeptide, was isolated from Fusaria
extracts and likely is to be produced from tryptophan, isoleucine, a pipecolic acid and an amino
decane derivative. Three of the four residues are uncommon amino acids and active variants
of OSI-2040 in which the nitrogen methoxy group is substituted with hydrogen also have been
isolated. OSI-2040 refers to either methoxy or hydrogen substituted entity, which display
indistinguishable bioactivity. OSI-2040 was shown to increase both γ-globin transcription
[34] and fetal hemoglobin (HbF) accumulation using three distinct assays: the HbF e.l.i.s.a.
(Table 1), hemoglobin staining assays (benzidine colorimetric and LBA chemiluminescent
assays; data not shown) and a hemoglobin cation-exchange HPLC assay (data not shown).
Of the chemical compounds, 62 were selected based on potency, efficacy and relative lack of
cytotoxicity. Of these, 35 were aniline derivatives. More than twenty of the anilines are
condensed as either amides, ureas, or carboxamides. Activity profiles of selected compounds
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from each of the chemical classes are shown in Table 1. The anilides OSI-168961, the amide
OSI-102695 and the benzoyl OSI-169055 showed maximal transcriptional inductions of 3.2,
2.5 and 2.2 fold respectively, potencies in the nM EC50 range with cytotoxicity apparent at
>20 uM. The carbamate OSI-168992, and anilides OSI-97345 and OSI-168996, the phenylurea
OSI-101820, the phenyltriazol OSI-169170, the amino-triazine OSI-22121 and the
phenylhydrazone OSI-169040 exhibited maximal inductions ranging from 2 to 5.8 fold with
low uM potencies. In these assays OSI-2040 showed a 4.3 fold stimulation of γYAC reporter
activity after twenty four hours exposure with an EC50 of ~150nM and cytotoxicity, following
forty eight hours exposure in K562 cells in vitro, was apparent at concentrations >500nM. In
comparison, aza-cytidine showed transcriptional activity (γYAC) of 2.5 fold at 600nM with
cytotoxicity apparent at ~1 uM. The reference compounds sodium butyrate and hydroxyurea
showed little or no induction (<2 fold) of reporter expression after 24 hours exposure, but did
increase reporter expression and HbF accumulation after longer incubation periods. For
example both hydroxyurea (100 uM) and sodium butyrate (1 mM) increased K562/HS2γ
expression by 10 fold after 96 hours exposure, while in the same experiment OSI-2040 (0.3
uM) showed a 47 fold increase. The assays for globin protein, the HbF elisa and the benzidine
staining assay, generally were less sensitive. In K562 cells exposed to compounds for 72 hours
benzidine staining (measuring total globin protein) increased 8 fold for OSI-2040 (4.8 uM),
2.5 fold for hydroxyurea (200 uM), 3 fold for hydroxyurea (500 uM), ~1.5 fold for sodium
butyrate (1 mM) and 2.2 fold for sodium butyrate (5 mM). In the HbF elisa measurements in
K562 cell exposed to compound for 96 hours, hydroxyurea (200 uM), azacytidine (1 uM) and
OSI-2040 (100 nM) increased HbF 2.8 fold, 3.1 fold and 5.4 fold respectively, as shown in
Table 1. Sodium butyrate was not tested in the HbF elisa. These finding were generally true
of many compounds where, at non-cytotoxic concentrations, EC50 values for potency increased
with increased cell exposure time.
The selected compounds showed γ-globin-inducing activity in both K562 and primary human
progenitor cells in vitro. Primary peripheral hematopoietic progenitor cells were cultured
[33] under conditions resulting in the expansion and differentiation of erythroid cells and the
induction of γ-globin (approximately days 2 - 4) and β-globin (approximately days 4 –8). To
minimize donor to donor variation progenitor cells from 2 –3 donors were pooled in Phase II
culture (day 4) and HbF concentration measured by e.l.i.s.a.. A relatively short incubation
period of 96 hours was used to minimize potential in vitro. Seven independent experiments
were performed using duplicate cultures for each compound and with three e.l.i.s.a.
determinations for each data point. A 3-way ANOVA analysis of the data was performed
(compound vs concentration vs experiment; Table 1). Compound potencies generally were in
the low uM EC50 range, with HbF increases of 2 to 7.2 fold over concentrations from 0.8 uM
to 20 uM observed. The exception was OSI-2040 which showed significant (p<0.05) γ-globin-
inducing activity of 5.4 and 4.5 fold in K562 and human progenitor cells respectively, at low
nM concentration (100nM for K562 cells and 40nM for human progenitor cells). In
comparison, azacytidine at 1 uM showed inductions of 3.1 and 10 fold in K562 and human
progenitor cells respectively. Hydroxyurea showed γ-globin -inducing activity of 2.8 and 5.9
fold in K562 and human progenitor cells, though with low potency (>100 uM).
Directed screening for inducers of γ-globin transcription
In initial validation studies, approximately 80 compounds with known activities in cellular
signaling were evaluated in the K562/γYAC assay. The compounds acetohydroxamic acid
(urease inhibitor), genistein and quercetin (tyrosine kinase inhibitor), 12-phorbol 13-myristate
(protein kinase C activator), ionomycin and A23187 (calcium influx), N-acetyl cysteine (anti-
oxidant), phenamil (sodium channel blocker) and olomucine (cyclin-dependent kinase
inhibitor) induced γ-globin promoter-reporter activity by > 2 fold. Few of these compounds
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had sufficient potency (<10 uM) or tractable chemical structures for further evaluation.
However analogs of acetohydroxamic acid were further investigated.
Proprionic hydroxamic acid (PHA) increased reporter activity in K562/HS2γ at concentrations
>4 uM, with maximal activity observed at ~70 uM as shown in Figure 4. Figure 4 shows log
concentration in uM on the x-axis and fold increase in γ expression on the y-axis. Increases in
γ transcription were time dependent, ranging from 2.6 fold at 48 hours to 6.7 fold at 120 hours
of exposure to 100 uM PHA. Reducing PHA concentration to 20 uM diminished γ transcription
to 2.1 fold to 3.3 fold at 48 and 120 hours exposure respectively. Six hydroxamic acid analogs
were compared in order to assess possible structure activity relationships. All analogs, with
the exception of compound 15260, were found to increase HS2γ expression (Table 2). R-02210
showed markedly greater induction at early time points than PHA, NS43789 or R-44534,
despite showing similar maximal inductions of ~5 to 7 fold at or around 100 uM compound
concentration. Both R-02761 and NS41080 were more potent, with maximal activity observed
at ~20 uM. However NS41080 showed less time dependence to HS2γ induction and showed
a more pronounced leftward tail in the dose response curves, suggestive of a greater window
between the efficacious and cytotoxic compound concentrations.
Histone deacetylase inhibition and activation of cellular stress pathways
Short chain fatty acids such as butyrate have been shown to induce γ-globin transcription and
exhibit histone deacetylase inhibitory activity at relatively high concentrations [35]. The
potential for the γ-globin-inducing compounds to inhibit histone deacetylase activity in K562
cells was examined. Using anti-acetyl-histone antibody, increased acetylated histone was
clearly observed in cells exposed to OSI-2040 for 18 hours, but was not detected in K562 cells
treated with other γ-globin-inducing compounds (Figure 5A). In separate experiments,
proprionic hydroxamic acid also was shown to have histone deacetylase inhibitory activity in
K562 cells (Figure 5B). The OSI-2040 concentration used was 1 uM, which provides maximal
γ-globin inducing activity yet was below the 24 hour cytotoxic IC50.
Many of the γ-globin inducing compounds initially identified showed cytotoxicity, as measured
by a reduction in MTT conversion and by a sharp decline in reporter signal, at concentrations
at or somewhat above those required for maximal induction of transcription. To investigate
whether stress-responsive pathways form an obligate mechanism in γ-globin induction, the
active compounds OSI-97345, OSI-102695, OSI-101820, OSI-168996, OSI-168961,
OSI-169050, OSI-169170, OSI-2040 and 5-azacytidine were investigated for their ability to
induce the stress responsive promoters or response elements from c-jun (early-immediate stress
response), GADD153 (growth arrest and DNA damage), GST Ya (phase II metabolic enzyme),
HIF1RE (hypoxia response element), HSP70 (heat shock and protein damage), heme
oxygenase (oxidative stress), NFκB-RE (oxidative stress, DNA damage), NF-AT (calcium
signaling) and XRE (aryl hydrocarbon receptor activation). A panel of 9 stably transfected
HepG2 cells containing luciferase reporter genes linked to individual promoters and response
elements were exposed to each of the compounds along with an appropriate positive control
for each marker, in triplicate at 6 doses (5-fold serial dilutions) as described in Materials and
Methods.
Table 3 indicates stress markers which were significantly induced by each compound (> 2-fold
induction p = 0.05), the magnitude of the greatest observed induction (in fold-induction and
as a percentage of the maximum observed effect), the dose at which the highest induction was
observed and the p value obtained from a t-test of the triplicate dose points compared to the
12 negative controls in each case. Only treatments resulting in at least a 2-fold (p < 0.05)
increase in luciferase expression are shown. Shown is the concentration of compound at which
maximum induction of stress response was seen, fold increase in luciferase activity, % of
maximum observed increase and p value (t-test). Notably, all of the compounds, with the
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exception of OSI-169170, induced transcription of the XRE reporter construct, suggesting that
these compounds are able to bind and activate the aryl hydrocarbon receptor. OSI-97345 was
the most powerful inducer of XRE, causing a 5-fold increase in luciferase expression at a dose
of 16.7 uM. OSI-2040 was the most potent inducer of XRE, giving a 4-fold increase at 0.12
uM. Four of the compounds, OSI-2040, OSI-97345, OSI-102695 and OSI-169170 induced
expression from the HSP70 promoter. Increased expression of HSP70 would suggest that
exposure of cells to these compounds results in damage to proteins or a disruption of protein
synthesis or folding [36]. Induction of HSP70 driven luciferase expression by OSI-97345,
OSI-102695 and OSI-169170 was fairly weak (~2.5-fold) but OSI-2040 induced a 6.8-fold
increase in expression, comparable to that observed with the alkylating agent methane methyl
sulfonate (MMS). OSI-2040 also induced the GADD153 reporter construct which may indicate
a genotoxic potential [37], as well as the jun and NFκB-RE constructs. The level of induction
of GADD153 by OSI-2040 was small (2.1-fold) compared to that observed with MMS (15.2-
fold) and the effect of OSI-2040 on the jun and NF-kBRE constructs was also small.
OSI-169050 and OSI-169170 also weakly induced the GADD153 reporter construct (2.3 and
2.1-fold respectively). Neither OSI-169050 nor OSI-169170 significantly induced jun or NF-
κBRE, although both did induce the GST Ya construct, as did OSI-97345 and OSI-102695.
Expression of GST Ya is induced in response to a variety of electrophilic compounds and
phenolic antioxidants [38].
The HIF1RE construct was induced by the compounds OSI-168996, OSI-168961 and
OSI-169050, suggesting that these compounds elicit a hypoxia response in HepG2 cells. Our
own previous work with this cell line (unpublished results) has shown that the HIF1RE reporter
construct may be activated by compounds known to activate the AH receptor such as 3-
methylcholanthrene (MC) and benzo(a)pyrene (MC elicited a 3.7-fold increase in HIF1RE
driven luciferase expression in this study). Not all of the compounds which induced the XRE
construct also induced the HIF1RE construct however, indicating that the responses are not
completely equivalent.
DISCUSSION
Chemically diverse compounds which induce γ globin transcription through histone
deacetylase (HDA) inhibitory and distinct cell stress-associated mechanisms were identified.
These effects could be observed in both K562 cells and human primary progenitor cells. In
evaluating the screening systems employed, the isolated K562/HS2γ clones were considerably
more responsive the K562/γYAC clones to compounds which induce the transcription of γ-
globin, for example as observed in the frequency distribution data shown in Figure 3. This was
true both with known compounds like azacytidine and hydroxyurea and the novel compounds
identified here. Both HS2γ and γYAC K562 reporter cell lines identified compounds capable
of increasing γ-globin expression both in the reporter assays as well as in human primary
progenitor cells (Table 1).
The majority of the compounds which activated γ-globin transcription shared a common motif
of two aryl moieties separated by less than four angstroms using one, two and three bond linkers
of several types (urea, carbamate, amide, carbonyl, ether, thiourea, etc.). The phenyl
imidazoles, phenyl hydrazones and phenyl triazols also may fall into this general structural
class. Whether these compounds interact with the same cellular targets as the related, less potent
compound, hydroxyurea, or have distinct protein targets remains to be determined. The most
potent and efficacious activity was observed with the HDA inhibitor OSI-2040, which
markedly increased HbF both in established and primary erythroid cell cultures at low nM
concentration. The HDA inhibitory activity of OSI-2040 (termed apicidin by Merck) has been
reported by other investigators [39–41] and found to be more effective than trichostatin A and
MS-275 in stimulating histone hyperacetylation in K562 cells [39]. Proprionic hydroxamic
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acid also was shown to inhibit histone deacetylase, though with much lower potency and with
slower kinetics of both histone deacetylase inhibition and γ-globin induction. Both aceto- and
proprionic hydroxamic acids have been clinically investigated as urease inhibitors and showed
good aqueous solubility. The hydroxamates generally showed relatively poor potency (>20
uM) but exhibited substantial efficacy after long term exposure (96 hours) as shown for
proprionic hydroxamic acid in Figure 4.
One central question we investigated here was whether compounds which induce γ-globin
could be non-toxic at efficacious concentrations in vitro. The data obtained from screening of
>186,000 compounds and extracts suggest that for the vast majority of compounds tested some
degree of cytotoxicity is required for γ-globin induction. One of the better tolerated cytotoxic
chemotherapy agents which can increase HbF is hydroxyurea, sometimes used clinically in
combination with erythropoietin [28]. It has been proposed that hydroxyurea acts to stimulate
the synthesis of early erythroid progenitors capable of γ-globin transcription, presumably
through preferential ablation of a more mature cell compartment leading to progenitor cell
expansion. Recent data have shown hydroxyurea can activate p38 MAP-kinase in a sustained
fashion and attenuated extracellular signal-related kinase (ERK) and the jun N-terminal kinase
(JNK). Further, inhibition of p38 reduced the ability of hydroxyurea to stimulate globin
production in K562 cells [42], strengthening a role for p38 activation in hydroxyurea action.
In the case of the biaryl substituted ureas, amides and carbamates, the common mechanistic
response was the activation of the aryl hydrocarbon response pathway (XRE) and not the
activation of c-JUN. The mechanisms of these compounds were distinct from those of
OSI-2040 which has potent histone deacetylase inhibitory activity and a distinct gene
expression pattern as measured by microarray hybridization and by RT-PCR (J.H.
unpublished)). Alterations in cell cycling have been inversely correlated with transcription of
γ-globin [43]. One frequently used measure of cell cycling is the phosphorylation status of the
retinoblastoma protein (Rb), which is phosphorylated in the G1 to S transition. In T47D cells,
many of the γ-globin inducing compounds identified here cause the hypophosphorylation of
Rb, indicative of cell cycle arrest or delay (data not shown). Conversely, in preliminary
experiments the cdk inhibitors roscovitine and olomucine increased the expression of the γ-
globin reporter line HS2γ/K562 (data not shown), though their inductions were modest
compared to the HDA inhibitor OSI-2040. These data support the hypothesis that the biaryl
ureas, amides and carbamates act in part through cell cycle dependent mechanisms, though the
precise mechanisms by which these compounds act to alter the process of erythroid maturation
and F cell production remain a point of continued investigation. It should be stressed that not
all cytotoxic chemotherapeutic agents can induce the synthesis of HbF, indicating some degree
of specificity in the signaling pathway requirements for γ-globin induction. Further, while cell
cycle delay can contribute to induction of γ-globin transcription, other events, for example
alterations in chromatin structure, are likely required for full activation of γ-gene expression.
Even in the compounds identified here, which were selected for a relative lack of in vitro
toxicity, a significant (p<0.01) trend between maximal γ induction and onset of cytotoxicity
can be observed. The apparent outlier, PHA, may be explained by the relatively long period
of time (~96 hours) required for maximal γ transcription and the shorter time periods used for
stress gene measurement (<25 hrs). An onset of cytotoxicity was frequently observed at
concentrations close or at that required for maximal γ-globin induction, producing steep, bell-
shaped dose response curves (eg. Figure 4), strongly suggesting cell stress mechanisms form
an obligate part of γ-globin inducing action.
Here we have developed screening methods useful in identifying compounds which stimulate
γ-globin transcription and promote fetal hemoglobin production. The novel chemical
compounds identified here provide pharmacophores for the development of new HbF elevating
compounds for treatment of sickle disease and possibly Cooley’s anemia. They further provide
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tools by which the multiple mechanisms of pharmacological up regulation of γ-globin
transcription may be investigated.
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FIGURE 1.
A. K562/HS2γ luciferase screening construct. LCR hypersensitive site 2 (HS2) was linked to
the γ-globin proximal promoter and inserted 5′ to a luciferase reporter gene from P. pyralis.
TK-neo was added and the resulting plasmid DNA was linearized and stably integrated in K562
cells by electroporation. B. K562/γYAC luciferase screening construct. A luciferase reporter
gene was recombined into the Aγ-globin gene within a 540kb yeast artificial chromosome
(YAC; Groveld et al., 1996). Recombination was performed such that the ATG of luciferase
displaced the ATG of Aγ. The resulting luciferase’tagged’ γ-globin gene was stably integrated
in K562 cells by spheroplast fusion.
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FIGURE 2.
Flow schematic illustrating natural product extract and chemical compound progression
pathways.
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FIGURE 3.
Frequency distribution of fold transcription increases resulting incubation with chemical
compound or fungal extracts. The y-axis records fold induction relative to vehicle control (0.2%
DMSO). Compounds/extracts are distributed along the x-axis, which has no units. A) HS2γ
cells exposed to compounds (scale 0 – 10); B) HS2γ cells exposed to fungal extracts (scale 0
– 100); C) γYAC cells exposed to compounds (scale 0 – 7); and D) γYAC cells exposed to
fungal extracts (scale 0 – 17). Fold induction of 1 indicates no effect, while inductions <1
indicate cytotoxicity and/or repression. Clusters reflect related compounds in close proximity
within the chemical and fungal extract libraries. Shading in panels B and D reflect different
fungal growth conditions.
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FIGURE 4.
Dose response activity profile of K562/HS2γ cells exposed to proprionic hydroxamic acid
(PHA) for 48, 72, 96 or 120 hours. Log concentration is indicated on the x-axis. Fold γ-globin
transcriptional increase is shown on the y-axis.
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FIGURE 5.
A. OSI-2040 treatment increases histone H4 acetylation in K562 cells. K562 cells were treated
for 24 hours with maximally acting concentration of OSI-97345 (lane 1), OSI-102695 (lane
2), OSI-22121 (lane 3), OSI-101820 (lane 4), OSI-168992 (lane 5), OSI-168996 (lane 6),
OSI-168961 (lane 7), OSI-169050 (lane 8), OSI-169170 (lane 9), OSI-2040 (lane 10) or 0.2%
DMSO (lane 11). Extracts were subjected to SDS-PAGE, transferred to nitrocellulose and
probed with anti-acetyl histone H4 antibody (Upstate Biotechnology, VA). Acetyl-histone H4
(11 kDa) was observed extracts from OSI-2040 treated cells, but not in extracts from cells
exposed to 0.2% DMSO or compounds OSI-97345 – OSI-169170. Weak reactivity of the
antibody to acetylated-histone H2B (14 kDa) may contribute to band broadening. B. Proprionic
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hydroxamic acid stimulates histone H4 acetylation in K562 cells. K562 cells were treated for
24 hours with 0.2% DMSO vehicle (lane 1), 10 uM proprionic hydroxamic acid (lane 2), 100
uM proprionic hydroxamic acid (lane 3), 1 uM OSI-2040 (lane 4) histones extracted and probed
with anti-Ac histone antibody as described for Figure 5A. The OSI-2040 concentration of 1
uM provides maximal γ-globin inducing activity yet was below the 24 hour cytotoxic IC50.
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TABLE 2
Activity of hydroxamate containing analogues in stimulating γ-globin transcription after 96 hours exposure in
K562/HS2γ cells.
Compound Structure EC50 (uM) Maximal Fold
Induction
acetohydroxamic acid 250 2.6
propionohydroxamic acid 30 4.7
R-02210 50 5.5
R-02761 4 3
R-44534 50 4.1
15260 - no effect
NS41080 5 4
NS43789 40 4
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TABLE 3
Maximum fold inductions of 9 stress response reporter constructs by γ-globin transcription inducing and control
compounds.
Compound [Compound] μ M Markers Induced
>2 Fold (p ≤ 0.05)
Fold
Induction
% Max p
Control Compounds
3-Methyl Cholanthrene 20 GST Ya (8 hr) 2.7 20 0.007
20 GST Ya (24 hr) 5.0 100 0.004
7 HIF1RE 3.7 100 0.006
20 XRE 5.5 48 0.001
Calcium ionophore (A23187) 2 HSP70 3.3 8 0.020
20 NF-AT 11.4 100 0.001
Methane methyl sulfonate (MMS) 1000 CJUN 10.1 100 0.000
1000 GADD153 15.2 58 0.000
333 GST Ya (8 hr) 4.7 40 0.012
333 HSP70 5.9 24 0.036
333 XRE 2.1 12 0.004
12-phorbol 13-myristate (PMA) 0.7 CJUN 8.1 78 0.000
0.2 GADD153 25.5 100 0.001
0.7 GST Ya (8 hr) 10.2 100 0.001
0.2 HMO 19.8 100 0.001
0.2 HSP70 21.7 100 0.004
0.7 NF-κ BRE 1030.0 100 0.004
2 NF-AT 8.6 60 0.029
0.7 XRE 10.2 98 0.019
Test Compounds
OSI-97345 17 GST Ya (8 hr) 2.5 16 0.005
17 GST Ya (24 hr) 2.8 38 0.010
6 HSP70 2.4 7 0.028
17 XRE 5.0 44 0.000
OSI-102695 4.2 GST Ya (24 hr) 2.0 18 0.043
1.4 HSP70 2.1 4 0.043
13 XRE 2.5 16 0.003
OSI-101820 14 XRE 2.9 20 0.001
OSI-168992 1.9 HIF1RE 2.2 48 0.000
0.6 XRE 2.8 20 0.003
OSI-168961 8 HIF1RE 2.4 79 0.035
3 XRE 2.3 15 0.006
OSI-169050 14 GADD153 2.3 6 0.004
42 GST Ya (8 hr) 2.3 13 0.009
125 GST Ya (24 hr) 2.5 27 0.003
42 HIF1RE 3.3 95 0.000
42 XRE 3.9 32 0.002
OSI-169170 42 GADD153 2.1 5 0.001
14 GST Ya (8 hr) 2.1 12 0.019
OSI-2040 10 CJUN 2.0 11 0.006
10 GADD153 2.1 4 0.000
0.4 HSP70 6.8 28 0.022
10 NF-κ BRE 4.1 0 0.022
0.1 XRE 4.2 34 0.006
Proprionohydroxamic acid (PHA) < 50 None - - -
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